Mark Zimering

Department of Veterans AffairsAustralia

Dr. Mark Zimering is the Chief of Endocrinology at the Department of Veterans Affairs in East Orange, New Jersey and Associate Professor of Medicine Co-Terminous at UMDNJ/Robert Wood Johnson Medical School. Dr. Zimering received his undergraduate training at Harvard College, MD and PhD degrees from the Albert Einstein College of Medicine, and completed an endocrinology fellowship at the NIH. His research has focused on roles for basic fibroblast growth factor (or autoantibodies which mimic or inhibit its effects) in diabetic vascular complications. He reported markedly increased plasma basic fibroblast growth in a subset of obese adult participants from the Veterans Affairs Diabetes Trial having increased coronary heart disease occurrence. His group reported low levels of plasma basic fibroblast growth factor in adult diabetes having a cluster of microvascular complications (macular edema, albuminuria, painful neuropathy) in association with endothelial cell inhibitory autoantibodies which activated the RhoA/Rho kinase signaling pathway in endothelial cells or caused global increases in intracellular calcium in endothelial cells, neurons or cardiomyocytes.

2books edited

Latest work with IntechOpen by Mark Zimering

Type 2 diabetes is estimated to affect 120 million people worldwide- and according to projections from the World Health Organization this number is expected to double over the next two decades. Novel, cost-effective strategies are needed to reverse the global epidemic of obesity which is driving the increased occurrence of type 2 diabetes and to less the burden of diabetic vascular complications. In the current volume, Topics in the Prevention, Treatment and Complications of Type 2 Diabetes, experts in biology and medicine from four different continents contribute important information and cutting-edge scientific knowledge on a variety of topics relevant to the management and prevention of diabetes and related illnesses.

Go to the book